AstraZeneca‘s COVID-19 vaccine and offered them to the public without health officials properly inspecting the operations of the U.S.
manufacturer, according to inspection records and the regulators involved.The Baltimore plant belonging to Emergent BioSolutions Inc was producing vaccines for both AstraZeneca Plc and Johnson & Johnson under a $628 million U.S.